First results from the prospective national intersectoral cohort study JADE to assess characteristics, treatment and outcome of patients with hepatocellular or cholangiocellular carcinoma in Germany. 3. Dezember 2022 Thimme R., Schröder J., Uhlig J., Freiberg-Richter J., Zingerle M.; Schlenska-Lange A., Hering-Schubert C., Potthoff K., Bengsch F., Hillebrand L.E., Siebenbach H.U., Jänicke M., Hofmann W.P., Pereira P., Galle P.R., Berg T., JADE Registry Group, 2022. Oncol Res Treat 2022; 45(suppl 1) (P211), 80. Link Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315. Gröschel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, et al. Oncol Res Treat. 2022;45(suppl 1)(Abstract 135):148. Download… Weiterlesen Implementation of new tests and treatments for patients with advanced triple negative breast cancer in routine care – data from the registry platform OPAL Zahn MO, Welt A, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. Oncol Res Treat. 2022;45(suppl 1)(246):23. Download… Weiterlesen